What is Wedbush's price target for IBM?
Wedbush has increased its price target for IBM to $325 from $300.
Yanuki
ARTICLE DETAIL
Wedbush Boosts IBM Target to $325 on AI-Fueled Growth | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026 | Wedbush Boosts IBM Target to $325 on AI-Fueled Growth | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026
Finance / Tech
Wedbush Boosts IBM Target to $325 on AI-Fueled Growth
Wedbush has increased its price target for IBM, citing the company's potential for AI-driven growth. The firm anticipates strong demand for IBM's software, cloud, and AI solutions, positioning IBM as a key player in the evolving tech landsc...
Key Insights
- Wedbush raised IBM's price target to $325 from $300, maintaining an Outperform rating.
- The firm highlights robust demand for IBM's software, cloud, and AI offerings, particularly WatsonX, AI agents, Red Hat, and OpenShift.
- IBM's GenAI book is valued at over $6 billion, expected to drive top-line expansion.
- Wedbush projects that 75% of AI workloads will run in containers by 2027, benefiting IBM's containerized AI solutions.
- IBM's quantum computing initiatives, including the Quantum Nighthawk chip and Quantum Starling platform, position it for long-term growth.
In-Depth Analysis
Wedbush's analysis points to several factors driving IBM's potential growth. The increasing adoption of hybrid cloud environments, coupled with the rising demand for AI solutions, positions IBM favorably. The firm's expertise in enterprise IT and its comprehensive portfolio of AI products and services differentiate it from competitors. IBM's early investments in quantum computing also provide a long-term growth avenue. Investors should closely monitor IBM's GenAI revenue, container penetration rates, and progress in quantum computing to assess the company's performance against the $325 target.
IBM is also included in Wedbush's AI 30 list, reflecting conviction that it's underowned despite strong YTD performance.
FAQ
What factors are driving Wedbush's positive outlook on IBM?
Wedbush cites strong demand for IBM's software, cloud, and AI offerings, as well as its early investments in quantum computing.
What is IBM's GenAI book valued at?
IBM's GenAI book is valued at over $6 billion.
Takeaways
- Monitor IBM's GenAI revenue and container penetration rates.
- Keep an eye on IBM's progress in quantum computing.
- Understand that IBM's focus on AI and hybrid cloud is likely to lead to growth.
Discussion
Do you think IBM's focus on AI and hybrid cloud will drive its stock price to $325? Let us know!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.